AzTrials
AzTrials

AdiposityNCT05992688

The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)

A study testing Sucrose sweetened beverage, Stevia sweetened beverages and Calorie free flavored water beverage in people with Adiposity and Insulin Sensitivity, run by Arkansas Children's Hospital Research Institute at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is an 8 to14-week three-arm randomized controlled in children 8 to 12 years old. The main purpose of the study is to evaluate if stevia has benefits for weight control and metabolic function relative to caloric sweeteners, and whether it provides benefits in this regard similar to water. Read more about this study

Who is it for?
Ages 8 to 12 yearsHealthy volunteers can take part
Conditions the study is for
Adiposity, Insulin Sensitivity, Weight Gain
What is being tested?
Sucrose sweetened beverage, Stevia sweetened beverages and Calorie free flavored water beverage
Could I receive a placebo?
No, everyone receives an active treatment
How many people
106 participants
Where
1 siteUnited States
Study dates
20 Dec 2023to 23 Mar 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 12 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Age 8-12 years
  • Normal weight: BMI percentile ≥5th to <85th
  • Excessive weight: BMI percentile ≥ 85th and <140% of the 95th percentile or BMI ≥35 to <40 kg/m2
  • Current consumption of sugar sweetened beverages (≥2 times /wk)
  • Low consumption of non-nutritive sweeteners (≤ 3 time/wk)
  • Willingness to consume experimental products Exclusion Criteria
Show all 29Show fewer
  • Children with class 3 obesity (i.e., BMI ≥ 140% of the 95th percentile or BMI ≥ 40.0 kg/m2)
  • Dislike of experimental beverage taste (assessed at initial visit)
  • Asthma that requires daily use of inhalers to keep symptoms under control.
  • Asthma that requires use of rescue inhalers (e.g., albuterol) >2 days per week
  • Exercise induced asthma.
  • Autism spectrum disorder (e.g., Autistic disorder, Rett disorder, Asperger disorder, childhood disintegrative disorder, pervasive developmental disorder not otherwise specified (PDD-NOS).
  • Attention deficit hyperactivity disorder (ADHD) currently under medication.
  • Oppositional defiant disorder (ODD).
  • Epilepsy.
  • Cancer.
  • Chronic kidney disease.
  • Endocrine disorder (e.g., hypothyroidism and growth hormone deficiency).
  • Autoimmune diseases (e.g., lupus, thyroiditis, juvenile idiopathic arthritis)
  • Bleeding disorders (e.g., hemophilia)
  • Chronic infections (e.g., HIV, hepatitis B, hepatitis C).
  • Mental health disorders (e.g., depression and anxiety).
  • Type 2 and type 1 diabetes mellitus.
  • Other pre-existing medical conditions or medications as determined by the investigators to affect the outcomes of interest.
  • If, during the screening or consent process, the parent or child expresses refusal to have blood drawn. However, participants may remain in the study if after initially agreeing to the blood draw and enrolling they change their minds and choose not to allow blood draws or if blood draws are unsuccessful.
  • Dislike of study products assessed at initial visit.
  • Fasting glucose ≥126 mg/dl at enrollment.
  • Fasting A1C ≥6.5% at enrollment
  • Less than 2 months since completion of antibiotics

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Arkansas Children's Nutrition Center

    Little Rock, Arkansas, 72202

Other trials in United States

About this study

This is an 8 to14-week three-arm randomized controlled in children 8 to 12 years old.

The main purpose of the study is to evaluate if stevia has benefits for weight control and metabolic function relative to caloric sweeteners, and whether it provides benefits in this regard similar to water.

Read the detailed description

Up to 150 children will be enrolled in the study to achieve a final sample of 90 completers (30 per group). The proposed study will be an 8 to 14-week, three-arm, randomized, controlled, blinded trial in children ages 8 to 12 years from the Central Arkansas region. Children will be randomized to consume one of three beverages: 1) sucrose-sweetened beverage, 2) stevia-sweetened beverage, or 3) calorie-free flavored water beverage. Participants with excessive weight (BMI percentile ≥85th and <140 percent of the 95th percentile) will complete a 14-week intervention whereas normal-weight (BMI percentile <85th) participants will complete an 8-week intervention in parallel.

Being tested
Sucrose sweetened beverage, Stevia sweetened beverages, Calorie free flavored water beverage
Keywords
Cardiometabolic health
Medical subject headings
Obesity, Insulin Resistance, Weight Gain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sucrose sweetened beverageOther

    Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 14 weeks.

  • Stevia sweetened beveragesOther

    Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 14 weeks.

  • Calorie free flavored water beverageOther

    Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 14 weeks.

Study groups in NCT05992688
Study groupRoleWhat they receive
Sucrose sweetened beverageActive comparatorSucrose (i.e. sugar): 31.2 g sugar (124.8 Kcal per serving). Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
Receives: Other: Sucrose sweetened beverage
Stevia sweetened beverageExperimentalThe stevia-sweetened beverage contains 48.6 mg of steviol equivalents. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
Receives: Other: Stevia sweetened beverages
Calorie free flavored water beverageActive comparatorFlavored water. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
Receives: Other: Calorie free flavored water beverage

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body mass index (BMI) z-scores

    The change in BMI z-score will be calculated: BMI z-score at completion of the study minus BMI z-score at baseline

    Measured: Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

  2. Fat mass index z-scores

    The change in fat mass index (FMI) z-score will be calculated: FMI z-score at completion of the study minus FMI z-score at baseline.

    Measured: Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

  3. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    HOMA-IR is a unitless estimate of insulin resistance, and it is calculated from fasting glucose and insulin

    Measured: Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

  4. Fasting plasma lipids (Total cholesterol, HDL-cholesterol, triglycerides, LDL-cholesterol)

    Fasting plasma lipids, mg/dl

    Measured: Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

  5. Blood pressure percentiles

    Systolic and diastolic blood pressure percentiles calculated using reference standards from the American Academy of Pediatrics.

    Measured: Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

Secondary outcomes (1)
  1. Gut microbial communities

    Shift in gut microbial communities will be assessed using 16S analyses

    Measured: Measurements will be obtained at enrollment (baseline) and again at week 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2023
  2. Study start20 Dec 2023
  3. Primary completion23 Mar 2026
  4. Study completion23 Mar 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
106 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05992688
Sponsor's protocol ID
275844
Status last verified
Oct 2026
First submitted
8 Aug 2023
Last updated
15 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: All study subject materials will be assigned a unique identifying code or number. The key to the code will be kept in a shared network folder with access granted only to study staff who have had appropriate CITI training. Only study investigators/staff will have access to the code and information that identifies the subject in this study. Coded data for all primary and secondary outcomes as well as secondary data analysis will be shared with the Sponsor (Cargill Corporation) using an approved shared folder .

Questions about this trial

What is this clinical trial studying?

A study testing Sucrose sweetened beverage, Stevia sweetened beverages and Calorie free flavored water beverage in people with Adiposity and Insulin Sensitivity, run by Arkansas Children's Hospital Research Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 29 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body mass index (BMI) z-scores (time frame: Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in